<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<title>Robson (Trustee of) v. Robson (October 12, 2004)</title>
<style><!--
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:553679495 -2147483648 8 0 66047 0;}
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
h1
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	tab-stops:right 6.0in;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;
	mso-ansi-language:EN-US;
	font-weight:normal;}
h2
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:1.5in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	mso-bidi-font-weight:normal;
	text-decoration:underline;
	text-underline:single;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{text-align:justify;
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{text-align:justify;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-pagination:widow-orphan;
	background:navy;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.Headingnumber, li.Headingnumber, div.Headingnumber
	{mso-style-name:"Heading number \[ \]";
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l1 level1 lfo1;
	tab-stops:right .5in 1.0in 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingNUMBER0, li.headingNUMBER0, div.headingNUMBER0
	{mso-style-name:"heading\: NUMBER";
	text-indent:-.45in;
	mso-pagination:widow-orphan;
	mso-list:l1 level2 lfo1;
	tab-stops:list .5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingsubtitle, li.headingsubtitle, div.headingsubtitle
	{mso-style-name:"heading\: subtitle";
	text-indent:-.5in;
	mso-pagination:widow-orphan;
	mso-list:l1 level4 lfo1;
	tab-stops:list 1.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.HeadingQuote, li.HeadingQuote, div.HeadingQuote
	{mso-style-name:"Heading \0022Quote\0022";
	mso-style-parent:"Heading number \[ \]";
	mso-pagination:widow-orphan;
	tab-stops:right .5in 1.0in 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.1Paragraph, li.1Paragraph, div.1Paragraph
	{mso-style-name:1Paragraph;
	mso-style-parent:"";
	mso-pagination:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
@page Section1
	{size:8.5in 11.0in;
	mso-header-
	mso-footer-
	mso-title-page:yes;
	mso-header: url(C37761.htm) h1;
	mso-even-footer: url(C37761.htm) ef1;
	mso-footer: url(C37761.htm) f1;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@list l0
	{mso-list-id:193661700;
	mso-list-template-ids:-1557382346;}
@list l0:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%2\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level4
	{mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level7
	{mso-level-text:"%7\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:"%8\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l0:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l1
	{mso-list-id:867135611;
	mso-list-template-ids:-1128621242;}
@list l1:level1
	{mso-level-text:"\[%1\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l1:level2
	{mso-level-style-link:"heading\: NUMBER";
	mso-level-text:"%2\)";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.45in;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l1:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:"%3\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l1:level4
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: subtitle";
	mso-level-text:"\(1\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l1:level5
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level6
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2
	{mso-list-id:1325932650;
	mso-list-type:hybrid;
	mso-list-template-ids:1714713828 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l2:level1
	{mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l3
	{mso-list-id:1772050197;
	mso-list-type:hybrid;
	mso-list-template-ids:-206406006 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l3:level1
	{mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l4
	{mso-list-id:1988700731;
	mso-list-template-ids:-1557382346;}
@list l4:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level2
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%2\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level4
	{mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level5
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level7
	{mso-level-text:"%7\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level8
	{mso-level-number-format:alpha-lower;
	mso-level-text:"%8\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
@list l4:level9
	{mso-level-number-format:roman-lower;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;}
ol
	{ul
	{-->
</style>
</head>
<body lang=EN-CA style='tab-interval:.5in' bgcolor="#FFFFFF">
<div class=Section1> 
  <p class=MsoHeader align="right"><span lang=EN-US>DATE:<span style="mso-spacerun: yes">  
    </span>20041012<br>
    </span><span lang=EN-US>DOCKETS:<span style="mso-spacerun: yes">  </span>C37761, 
    C39245 and C41387</span></p>
  <p class=MsoBlockText><span lang=EN-GB>IN THE MATTER OF THE BANKRUPTCY OF PAUL 
    ALEXANDER ROBSON, OF THE CITY OF TORONTO, IN THE PROVINCE OF ONTARIO</span><span
lang=EN-GB style='font-size:13.0pt;mso-bidi-font-size:10.0pt'></span></p>
  <h1><span lang=EN-US style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>COURT 
    OF APPEAL FOR ONTARIO</span></h1>
  <p class=MsoNormal><span
lang=EN-US>RE:<span style='mso-tab-count:1'>                 </span><span
style='mso-tab-count:1'>            </span></span><span lang=EN-GB
style='mso-ansi-language:EN-GB'>TESSIS &amp; PARTNERS RECEIVERS AND TRUSTEES INC. 
    AS TRUSTEES OF THE ESTATE OF PAUL ALEXANDER ROBSON (Plaintiff/Respondent) 
    -and- PAUL ALEXANDER ROBSON, ANTI-AGING HOLDINGS LIMITED, RX CORPORATION and 
    CELLEX-C INTERNATIONAL INC. (Defendants/Appellants)</span></p>
  <p class=MsoNormal><span lang=EN-US>BEFORE:<span
style='mso-tab-count:1'>                        </span>BORINS, LANG and JURIANSZ 
    JJ.A.</span></p>
  <p class=MsoNormal><span lang=EN-US>COUNSEL:<span
style='mso-tab-count:1'>                    </span>Paul Alexander Robson</span><span lang=EN-US><span
style='mso-tab-count:1'>  </span>the appellant </span><span lang=EN-US>in person 
    and </span><span lang=EN-US>for the appellant RX</span></p>
  <p class=MsoNormal><span lang=EN-US><span
style='mso-tab-count:1'>                        </span><span
style='mso-tab-count:1'>            </span><span
style='mso-tab-count:1'>    </span>John B. Laskin and Sean E. Cumming f</span><span lang=EN-US>or 
    the appellants </span><span lang=EN-US>Anti-Aging Holdings Limited and Cellex-C 
    International Inc.</span></p>
  <p class=MsoNormal><span lang=EN-US><span
style='mso-tab-count:1'>                 </span><span lang=EN-US><span
style='mso-tab-count:1'>            </span></span><span
style='mso-tab-count:1'>           </span>Hillel David and Richard Howell</span><span lang=EN-US> 
    for the respondent </span><span lang=EN-US>Tessis &amp; Partners</span></p>
  <p class=MsoNormal><span lang=EN-US>HEARD:<span
style='mso-tab-count:1'>                        </span>September 7, 2004 </span></p>
  <p class=MsoBodyText align=left style='text-align:left'><span lang=EN-US>Appeals 
    C37761 and C39245 are from the judgment of Justice Joan L. Lax of the Superior 
    Court of Justice dated February 1, 2002, as amended by supplementary reasons 
    dated June&nbsp;3, 2002.<span style="mso-spacerun: yes">  </span>Appeal C41387 
    is from the order of Lax J. dated February 9, 2004 reported at [2004] O.J. 
    No. 55. </span></p>
  <h2><span lang=EN-US>ENDORSEMENT</span></h2>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>These appeals primarily question whether the 
    trial judge erred in finding that Paul Robson acquired certain property while 
    he was an undischarged bankrupt between July 8, 1992 and May 15, 1996 and 
    whether Mr.&nbsp;Robson diverted any such property, and funds arising from 
    that property, in violation of the <i style='mso-bidi-font-style:normal'>Bankruptcy 
    and Insolvency Act</i>, R.S.C. 1986, c. B-3, (the “Act”), in particular, 
    pursuant to the Act’s<i> </i>provisions regarding “after-acquired property” 
    (s. 67(1)(c)).<span style="mso-spacerun: yes">  </span></span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[2]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The appellants also challenge the following 
    findings made by the trial judge:</span></p>
  <p class=MsoNormal style='
mso-list:l2 level1 lfo3;'> <span
lang=EN-US>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The bankruptcy court had jurisdiction over 
    Anti-Aging Holdings Limited (“AAH”) and Cellex-C International Inc. (“Cellex”) 
    who were “strangers to the bankruptcy”; </span></p>
  <p class=MsoNormal style='
mso-list:l2 level1 lfo3;'> <span
lang=EN-US>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>AAH and Cellex are accountable to the trustee 
    for monies paid on account of Mr. Robson’s share ownership; </span></p>
  <p class=MsoNormal style='
mso-list:l2 level1 lfo3;'> <span
lang=EN-US>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>AAH and Cellex were accountable for additional 
    monies demanded by the trustee at the time the judgment was settled without 
    adequate opportunity for them to make submissions and without adequate reasons 
    by the trial judge; </span></p>
  <p class=MsoNormal style='
mso-list:l2 level1 lfo3;'> <span
lang=EN-US>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Mr. Robson was required to elect to call no 
    evidence before proceeding with his motion for non-suit; and</span></p>
  <p class=MsoNormal style='
mso-list:l2 level1 lfo3;'> <span
lang=EN-US>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The plaintiffs were entitled to costs on a 
    substantial indemnity basis.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[3]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The main issue on appeal rests on the trial 
    judge’s finding that the bankrupt, Mr.&nbsp;Robson, acquired shares in AAH 
    and, through AAH, in Cellex at a time when he remained an undischarged bankrupt.<span style="mso-spacerun: yes">  
    </span>While the intended owner of the shares was initially said to be Paul 
    Robson, the share certificates were eventually issued to his wife’s company 
    RX Corporation (“RX”), which the trial judge concluded to be an “artifice” 
    and equivalent to issuing the shares to Mr. Robson<i>.</i></span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[4]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The appellants say that the shares at issue 
    were given to Mr. Robson through RX after his bankruptcy and hence could not 
    be subject to any claim by the bankruptcy<span style="mso-spacerun: yes">  
    </span>trustee. To establish a gift of the shares to Mr. Robson during the 
    bankruptcy, the trustee was required to prove, among other elements, that 
    the shares had been delivered in a manner that provided Mr. Robson with a 
    legally enforceable entitlement to the shares. The appellants argued that 
    the trustee failed to establish this essential element of gift.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[5]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>This was not a case, however, where Mr. Robson 
    had nothing more than a promise to receive the shares at a future date; rather, 
    it was a case where the trial judge found that Mr. Robson had an actual ownership 
    interest from June 21, 1993, from which flowed his interest in the shares 
    in question and the income arising from those shares. In our view, there was 
    more than ample evidence to support these findings. </span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[6]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>That evidence included:</span></p>
  <p class=headingNUMBER0> <span lang=EN-US>i)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Mr. Robson’s sworn affidavit in another proceeding 
    that he had been a shareholder during the time of his bankruptcy; </span></p>
  <p class=headingNUMBER0> <span lang=EN-US>ii)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Corporate documentation evidencing his 1993 
    share ownership;</span></p>
  <p class=headingNUMBER0> <span lang=EN-US>iii)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Mr. Robson’s later directions to his law clerk 
    to alter the corporate records to amend the date of his share ownership; and 
    </span></p>
  <p class=headingNUMBER0> <span lang=EN-US>iv)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Meagan McLellan’s evidence in another proceeding 
    that Mr. Robson was a shareholder in 1993. (Ms. McLellan was the principal 
    witness for Mr.&nbsp;Robson at trial.)</span></p>
  <p class=MsoBodyText align=left style='text-align:left'><span lang=EN-US>Further, 
    there was evidence to support the finding that Mr. Robson’s share ownership 
    entitled him to an interest in Cellex.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[7]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>While in her initial reasons the trial judge 
    did not appear to differentiate between payments to Mr. Robson through RX 
    on account of share ownership and payments on account of work contributed 
    by him, in her February 9, 2004 confirmation of the Registrar’s Report, the 
    trial judge clearly found that the payments related to RX’s percentage ownership 
    of the shares and not to legal services performed by Mr. Robson. Further, 
    the trial judge was entitled to conclude on the evidence that the monies paid 
    accrued during and were attributable to the period of Mr. Robson’s bankruptcy. 
    Further, while the appellants raised the applicability of s. 68 of the <span
style='mso-bidi-font-style:italic'>Act</span>, that section cannot apply retrospectively 
    to income not disclosed by the bankrupt and of which the trustee was unaware 
    during the bankruptcy period.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[8]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>On the question of jurisdiction, this was 
    determined by Spence J. on the motion of Mr. Robson and RX.<span
style="mso-spacerun: yes">  </span>On January 17, 2002, he ruled that the issues 
    raised by these proceedings are within the jurisdiction of the Bankruptcy 
    Court. Jurisdiction was not, and is not, challenged by Cellex or by AAH. As 
    Mr. Robson has not pursued an application for leave to appeal from the ruling 
    of Spence J., he is unable to raise the jurisdictional issue before this court.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[9]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>In addition to her findings against Mr.&nbsp;Robson 
    and RX, the trial judge made credibility findings against Ms. McLellan. The 
    trial judge found Ms. McLellan to be the controlling shareholder and directing 
    mind of AAH, its affiliated company Anti-Aging International Inc. (“AII”), 
    Cellex, and its sister company Cellex Cosmaceuticals Inc. (“Cosmaceuticals”) 
    colluded with Mr. Robson to deprive the trustee in bankruptcy of the disputed 
    shares and of monies paid to RX in consequence of its ownership of those shares. 
    There was ample evidence to support a finding that “McLellan and Robson collaborated 
    to attempt to conceal assets from the Trustee”.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[10]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Given the findings about Ms. McLellan’s control 
    of and the interrelationship between her companies, the trial judge was entitled 
    to order an accounting not only by Mr. Robson and by RX, but also by Cellex 
    and AAH. Further, the evidence supported the trial judge’s finding that monies 
    paid by Cosmaceuticals amounted to “merely an internal allocation mechanism” 
    and were properly attributed to AAH and Cellex.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[11]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>With respect to the additional monies found 
    owing, the trial judge confirmed the Registrar’s Report and settled the judgment 
    after receiving further written submissions from all parties. The late disclosure 
    of monies paid by the other corporate appellants to RX mandated the inclusion 
    of those monies in the judgment. We have reviewed that correspondence and 
    are of the view that the parties had adequate opportunity to make submissions 
    with respect to the additional funds, which were similar in kind to the funds 
    already discussed in the trial judge’s reasons.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[12]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>With respect to Mr. Robson’s motion for non-suit, 
    the trial judge followed the accepted procedure in Ontario. There was no error 
    in her determination on either a procedural or a substantive basis.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[13]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Finally, on the costs issue, the appellants 
    seek leave to appeal and, if granted leave, appeal the trial judge’s award 
    of solicitor-and-client costs. While we grant leave to appeal the costs order, 
    we are of the view that there is no reason to interfere with the trial judge’s 
    exercise of discretion to award costs on a solicitor-and-client basis. In 
    making that award, the trial judge correctly applied the proper principles 
    and exercised her discretion to show disapproval of the appellants’ conduct 
    during the litigation.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[14]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>This case was primarily about credibility. 
    The trial judge’s findings on credibility were supported by the evidence. 
    We see no error, palpable or otherwise. Consequently, the appeals are dismissed.</span></p>
  <p class=Headingnumber style='line-height:normal'> <span
lang=EN-US>[15]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>The respondent is entitled to costs on a partial 
    indemnity basis. We have reviewed counsels’ written submissions on costs and 
    fix costs payable jointly and severally by all the appellants in the amount 
    of $23,000, inclusive of G.S.T. and disbursements. </span></p>
  <p class=MsoNormal><span lang=EN-US>Signed: “S. Borins J.A.”</span></p>
  <p class=MsoNormal><span lang=EN-US><span
style='mso-tab-count:1'>            </span></span><span lang=FR-CA
style='mso-ansi-language:FR-CA'><span style="mso-spacerun: yes">  </span>“S.E. 
    Lang J.A.”</span></p>
  <p class=MsoNormal><span lang=FR-CA style='mso-ansi-language:
FR-CA'><span style='mso-tab-count:1'>            </span><span
style="mso-spacerun: yes">  </span>“R.G. Juriansz J.A.”</span></p>
</div>
</body>
</html>
